Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Using our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet need. Our platform aims to leverage the unique biology of EBV T cells to channel the power of the immune system and has the potential to treat a wide range of diseases. Atara is applying this one platform to create a robust pipeline with the goal of developing treatments that improve the quality and longevity of patients’ lives. Atara’s pipeline includes tabelecleucel in Phase 3 development for EBV-driven post-transplant lymphoproliferative disease (PTLD) and in earlier stages of development for other EBV-associated diseases, ATA188 for multiple sclerosis, and next-generation CAR T therapies for solid tumors and hematologic cancers.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):